Nkarta, Inc.
NKTX · Pharmaceutical Preparations · 71.5M shares · +27%/yr ↑ dilution · EDGAR filings ↗
Reference price $2.71 · est. market cap ~$194M — last insider sale, 2026-06-18 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical/early-stage biotech — NK-cell-therapy clinical, heavy burn ($90M), very well-funded.
Strengths
- Liquidity — current ratio 12.7 (86th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Cash burnNegative free cash flow (-89.9M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +27%/yr over 3y (dilution, book value/share -59%)
- Strong balance sheetStrong balance sheet — $292M cash & investments, ~13 quarters of runway
- Notable holderHeld by 5 notable fund(s): CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP +2 more (as of 2026-03-31)
- Insider sellingInsider selling — 3 open-market sale(s) by 2 insider(s) (cluster of 2 insiders, last 6mo) Form 4 ↗
Quarterly revenue
Last 2 quarters · from SEC filings.
Key metrics
Return on equity
-33.3%
Return on assets
-25.8%
Current ratio
12.7×
Free cash flow
-$90M
EBITDA
-$113M
Tangible book value
$312M
Cash & investments
$292M
Cash runway
13q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-18 | HASTINGS PAUL J | Sell | 1.8K | $2.71 |
| 2026-01-15 | HASTINGS PAUL J | Sell | 26K | $2.07 |
| 2026-01-15 | Mahmood Nadir | Sell | 5.6K | $2.07 |
| 2026-01-06 | Rose Shawn Marshall | Grant | 70K | — |
| 2026-01-06 | Mahmood Nadir | Grant | 80K | — |
| 2026-01-06 | HASTINGS PAUL J | Grant | 94K | — |
| 2025-06-18 | HASTINGS PAUL J | Sell | 1.8K | $1.79 |
| 2025-01-15 | Shook David | Sell | 8.6K | $2.20 |
| 2025-01-15 | Levin Alyssa | Sell | 5.8K | $2.20 |
| 2025-01-15 | Brandenberger Ralph | Sell | 7.4K | $2.20 |
| 2025-01-15 | HASTINGS PAUL J | Sell | 17K | $2.20 |
| 2025-01-15 | Hager Alicia J. | Sell | 9.6K | $2.20 |
| 2025-01-03 | Shook David | Grant | 59K | — |
| 2025-01-03 | Levin Alyssa | Grant | 52K | — |
| 2025-01-03 | Brandenberger Ralph | Grant | 52K | — |
| 2025-01-03 | Hager Alicia J. | Grant | 52K | — |
| 2025-01-03 | Mahmood Nadir | Grant | 62K | — |
| 2025-01-03 | HASTINGS PAUL J | Grant | 94K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06733935 ↗ | A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) Systemic Sclerosis, Idiopathic Inflammatory Myopathies | PHASE1/PHASE2 | Recruiting | 2028-10-01 |
| NCT06557265 ↗ | A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) Lupus Nephritis, Primary Membranous Nephropathy | PHASE1/PHASE2 | Recruiting | 2027-04-01 |
| NCT05020678 ↗ | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia | PHASE1 | Active Not Recruiting | 2025-03-31 |
| NCT04623944 ↗ | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS Relapsed/Refractory AML, AML, Adult | PHASE1 | Active Not Recruiting | 2024-10-02 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-11 | Shareholder voteExhibits | filing ↗ |
| 2026-05-12 | ResultsExhibits | filing ↗ |
| 2026-03-26 | OtherExhibits | filing ↗ |
| 2026-03-25 | ResultsExhibits | filing ↗ |
| 2025-11-10 | ResultsExhibits | filing ↗ |
| 2025-08-12 | ResultsExhibits | filing ↗ |
| 2025-06-06 | Exec/director changeShareholder voteReg FDExhibits | filing ↗ |
| 2025-05-14 | ResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-11 | 2026-06-10 | 0001193125-26-267830 ↗ |
| 8-K | 2026-05-12 | 2026-05-12 | 0001787400-26-000012 ↗ |
| 10-Q | 2026-05-12 | 2026-03-31 | 0001787400-26-000013 ↗ |
| 8-K | 2026-03-26 | 2026-03-25 | 0001787400-26-000008 ↗ |
| 10-K | 2026-03-25 | 2025-12-31 | 0001787400-26-000006 ↗ |
| 8-K | 2026-03-25 | 2026-03-25 | 0001787400-26-000005 ↗ |
| 10-Q | 2025-11-10 | 2025-09-30 | 0001193125-25-274304 ↗ |
| 8-K | 2025-11-10 | 2025-11-10 | 0001193125-25-274261 ↗ |
| 8-K | 2025-08-12 | 2025-08-12 | 0001193125-25-178949 ↗ |
| 10-Q | 2025-08-12 | 2025-06-30 | 0001193125-25-178964 ↗ |
| 8-K | 2025-06-06 | 2025-06-03 | 0000950170-25-082717 ↗ |
| 10-Q | 2025-05-14 | 2025-03-31 | 0000950170-25-071455 ↗ |